One Asset Gained 2,300%
The Last Time This Setup Happened
Here’s What It Was
Dear Reader,
From 1970 to 1980, one specific asset gained more than 2,300%.
That’s not a typo. A $10,000 investment became $230,000 in a decade.
And here’s why we’re bringing it up right now.
The exact same conditions that produced that gain in the 1970s are forming again today.
Stagflation. The toxic combination of high inflation AND a stalled economy. The 1970s version trapped the U.S. economy in a vise for nearly a decade. Stocks went sideways for 10 years. Bonds got crushed. Cash lost half its value.
Now look at where we are:
Inflation expectations spiked to 4.8%. JP Morgan and Moody’s are warning of recession by 2026. Oil is surging on Middle East tensions. And the Fed is trapped – cut rates and inflation worsens, hike rates and recession arrives faster.
The setup is identical.
Now we know what you’re thinking. “That was 50 years ago. It can’t happen again.”
The smartest money in the world disagrees.
Central banks are loading up on the same asset that gained 2,300% in the 1970s – at the fastest pace in 50 years. JP Morgan is forecasting it could hit $8,000 before this cycle ends.
You’re going to make a decision today whether you realize it or not.
Position before stagflation locks in. Or watch from the sidelines while the same trade plays out again.
Because once the trap closes, getting out gets expensive.
Health Insurance Just Got 34% Pricier. Are Centene and Oscar Cheap or Cornered?
Hey there, bargain hunter. The first open enrollment season without the enhanced federal premium tax credits is now underway, and the numbers are ugly enough to make you look twice at the managed-care stocks sitting near multi-year lows.
Scoreboard
Insurers have asked state regulators for a median increase of 15 percent for 2027, according to KFF’s review of 276 filings covering all 50 states and Washington, D.C. That follows a 20 percent increase already baked into 2026 rates. For a 40-year-old non-smoking adult who is not eligible for subsidies and enrolls in a bronze plan, the monthly premium climbed from $381 in 2025 to $511 in 2027, a two-year increase of 34 percent. The enrollment damage from 2026 is already visible: marketplace enrollment fell from 21.8 million people in February 2025 to 19.2 million in February 2026, a decline of about 2.6 million people, or 12 percent, the steepest single-year decline since the marketplaces opened in 2014.
What Actually Happened
The drop traces back to the expiration of the ACA’s enhanced premium tax credits, which lowered enrollees’ monthly payments when they were in effect from 2021 through 2025 and had more than doubled marketplace enrollment between 2020 and 2024. When those enhanced subsidies expired, the “subsidy cliff” reemerged, causing many middle-income people to drop their coverage because they earned too much to qualify for standard subsidies but too little to afford unsubsidized premiums.
Adults between 18 and 34 accounted for a disproportionate share of the drop, the pattern insurers had predicted and the one that drives everything downstream: a risk pool loses its healthiest members first when the net price rises, because those are the members for whom coverage was closest to optional. Sicker enrollees stay. Premiums rise again. The cycle repeats.
The same adverse-selection dynamic is reshaping Medicare Advantage simultaneously. Eleven insurers exiting individual Medicare Advantage for 2027 are forcing hundreds of thousands of enrollees to find new coverage, compressing the risk pool from a second direction.
Eleven States Writing Cheques, Two Brand New
At least 11 states are offering state-funded premium help to ACA marketplace enrollees in 2027, with Rhode Island and Virginia debuting new programs. The states include California, Colorado, Connecticut, Maryland, Massachusetts, New Mexico, New Jersey, Rhode Island, Vermont, Virginia, and Washington state. California raised funding for its Covered California State Subsidy Program to $300 million in 2027 from $190 million. New Mexico is the only state fully replacing the enhanced federal subsidies for 2027. The proof is in the enrollment data: state-based marketplaces that run their own enrollment platforms saw a 6 percent decline in 2026 versus a 15 percent decline for states using the federal marketplace.
Is It Cheap?
Centene (CNC) is the more interesting valuation question. Centene had 3.4 million ACA marketplace members on September 30, down from 5.8 million a year earlier. That is a 41 percent membership collapse in its core exchange business. Yet the company raised its full-year guidance after Q2 and now expects at least $4.80 in earnings per share, with revenue guidance between $193.5 billion and $197.5 billion. CNC trades at a normalized price-to-earnings of 13.36 and a price-to-sales of 0.17, thin enough that the stock looks like a margin recovery play, not a growth story.
Oscar (OSCR) is the opposite trade. Membership reached 2.96 million as of June 30, 2026, up 46 percent year over year, while second-quarter revenues jumped to $4.88 billion. Oscar expects overall ACA marketplace membership to remain stable in 2027, positioning itself to gain share from approximately 850,000 lives displaced by competitor exits. The problem is price: at a recent price of $33.47, GuruFocus estimates the stock is 29.3 percent overvalued relative to intrinsic value.
Bull / Base / Bear
- Bull: Competitor exits hand Centene and Oscar a captive market. Centene, the largest exchange insurer in the nation, is expanding into 55 additional counties in Alabama, Iowa, Illinois, Louisiana, Michigan, New Jersey, and Texas. Higher premiums mean higher per-member revenue, which can rebuild margins even on a smaller book.
- Base: Enrollment stabilizes around 17 million nationally. CNC’s depressed P/S of 0.17 looks attractive. Oscar grows share but needs to prove earnings durability at scale.
- Bear: This is the second consecutive year of double-digit premium hikes. Whether states will be able to continue providing funding for their premium assistance programs depends on state budgets. A third year of large increases could push effectuated enrollment below 15 million, gutting the revenue base for everyone still in the market.
Action Plan
CNC is the cheaper of the two on every traditional metric. The enrollment attrition is largely priced in. If Q3 guidance holds, buy in thirds: a first tranche now, a second after the January 15 enrollment close confirms membership trends, a third if 2027 guidance lands above $5.00 EPS. OSCR’s growth story is real, but at current levels it demands execution. Hold existing positions; add only on a pullback toward $25.
Cheap Investor Checklist
- CNC normalized P/E: 13.36 vs. sector median above 20. Watch for further compression.
- CNC ACA marketplace membership: 3.4 million as of Q3. Any sequential gain in Q4 is a catalyst.
- OSCR membership: 2.96 million. Track Q4 open enrollment capture of the 850,000 displaced lives.
- State subsidy budgets: 11 states covering; fiscal year 2028 budget cycles will reveal sustainability.
- January 15 enrollment deadline: total effectuated sign-ups versus the 17 million baseline.
- Federal subsidy restoration: no bill has cleared Congress as of November 15, 2026. Any bipartisan movement changes the entire sector thesis.
- Risk pool age and morbidity: watch medical loss ratios in Q1 2027 earnings as the leading indicator.
Bottom Line
If ACA enrollment stabilizes near 17 million and state programmes cushion the worst-hit markets, CNC at a 0.17 price-to-sales is the kind of unloved story this publication exists to find. If a third consecutive year of double-digit premium increases pushes another 2 million people off coverage, those depressed multiples are depressed for a reason. The January 15 close is your first real data point. Watch membership, not the stock price, until then.
